Banner Photo
Clinical Trial Results
Indication Drug Name Study IDs Title Phase Result Details
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-001 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Three Fixed Doses Of Aripiprazole In The Treatment Of Patients With Acute Schizophrenia III Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-001 LT A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Three Fixed Doses Of Aripiprazole In The Treatment Of Patients With Acute Schizophrenia III Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-002 (26 week) A Multicenter, Randomized, Double-Blind Safety And Tolerability Study Of Flexible Doses Of Aripiprazole And Olanzapine In The Treatment Of Patients With Acute Schizophrenia III Publica-
tion
Reference
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-002 (26-52 week) A Multicenter, Randomized, Double-Blind Safety And Tolerability Study Of Flexible Doses Of Aripiprazole And Olanzapine In The Treatment Of Patients With Acute Schizophrenia III Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-003 A Multicenter, Double-Blind, Randomized Comparative Study Of Aripiprazole And Olanzapine In The Treatment Of Patients With Acute Schizhophrenia III Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-003 ST A Multicenter, Double-Blind, Randomized Comparative Study Of Aripiprazole And Olanzapine In The Treatment Of Patients With Acute Schizophrenia III Publica-
tion
Reference
Psychosis ABILIFY® (aripiprazole)
 CN138-004 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Of Three Fixed Doses Of Aripiprazole In The Treatment Of Institutionalized Patients With Psychosis Associated With Dementia Of The Alzheimer's Type III Result
Psychosis ABILIFY® (aripiprazole)
 CN138-004 LT A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Of Three Fixed Doses Of Aripiprazole In The Treatment Of Institutionalized Patients With Psychosis Associated With Dementia Of The Alzheimer's Type III Publica-
tion
Reference
/Result
Psychosis ABILIFY® (aripiprazole)
 CN138-005 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Aripiprazole In The Treatment Of Institutionalized Patients With Psychosis Associated With Dementia Of The Alzheimer's Type III Publica-
tion
Reference
/Result
Psychosis ABILIFY® (aripiprazole)
 CN138-005 LT A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Aripiprazole In The Treatment Of Institutionalized Patients With Psychosis Associated With Dementia Of The Alzheimer's Type III Publica-
tion
Reference
/Result
Psychosis ABILIFY® (aripiprazole)
 CN138-006 A Mulitcenter, Randomized, Double-Blind,Placebo-Controlled, Flexible Dose Study Of Aripiprazole In The Treatment Of Patients With Psychosis Associated With Dementia Of Alzheimer's Type III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-008 LT A Multicenter, Randomized, Double-Blind Study Of Aripiprazole And Haloperidol In The Maintained Response To Treatment For An Acute Manic Episode III Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-008 ST A Multicenter, Randomized, Double-Blind Study Of Aripiprazole And Haloperidol In The Maintained Response To Treatment For An Acute Manic Episode III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-010 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Aripiprazole In The Maintenance Treatment Of Patients With Bipolar Disorder III Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-012 A Randomized, Double-Blind, Comparison Of The Efficacy And Safety Of Aripiprazole Im Formula, Haloperidol, Or Placebo In The Treatment Of Acutely Agitated Patients With A Diagnosis Of Schizophrenia Or Shizoaffective Disorder III Publica-
tion
Reference
/Result
Mania ABILIFY® (aripiprazole)
 CN138-013 A Randomized, Double-Blind Comparison Of The Efficacy And Safety Of Aripiprazole Intramuscular Formula, Lorazepam Or Placebo In The Treatment Of Acutely Agitated Patients Diagnosed With Bipolar I Disorder, Manic Or Mixed III Publica-
tion
Reference
/Result
Clinical Pharmacology ABILIFY® (aripiprazole)
 CN138-022 Safety, Tolerability And Pharmacokinetics Of Aripiprazole And Carbamazepine Coadministration In Patients With Schizophrenia Or Schizoaffective Disorder I Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-032 A Multicenter, Randomized, Double-Blind Study Of Flexible Doses Of Aripiprazole Versus Perphenazine In The Treatment Of Patients With Treatment-Resistant Schizophrenia III No Data Available
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-032 LT A Multicenter, Randomized, Double-Blind Study Of Flexible Doses Of Aripiprazole Versus Perphenazine In The Treatment Of Patients With Treatment-Resistant Schizophrenia III Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-037 ST A Multicenter, Open-Label Long-Term Study Of The Safety, Tolerability And Efficacy Of Aripiprazole In The Maintenance Treatment Of Patients With Bipolar Disorder III Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-047 A Multicenter, Randomized, Double-Blind, Placebo Controlled, 26 Week Study Of A Fixed Dose Of Aripiprazole In The Treatment Of Stabilized Patients With Chronic Schizophrenia: Open-Label Randomized, 52 Week Extension Phase III No Data Available
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-047 ST A Multicenter, Randomized, Double-Blind, Placebo Controlled, 26 Week Study Of A Fixed Dose Of Aripiprazole In The Treatment Of Stabilized Patients With Chronic Schizophrenia III Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-050 Randomized, Double-Blind, Dose-Ranging Study Of Intramuscular Aripiprazole In The Treatment Of Acute Agitation In Patients With A Diagnosis Of Schizophrenia, Schizoaffective, Or Schizophreniform Disorder II/III Publica-
tion
Reference
/Result
Psychosis ABILIFY® (aripiprazole)
 CN138-060 A Pilot Open-Label, Flexible Dose Study To Evaluate The Safety And Tolerability Of Aripiprazole In Patients With Phychosis Associated With Parkinson's Disease II Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-074 A Multicenter, Randomized, Double-Blind Study Of Aripiprazole Versus Placebo In The Treatment Of Acutely Manic Patients With Bipolar Disorder III Publica-
tion
Reference
/Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-087 A Prospective, Multicenter, Open-Label Study Of Aripiprazole In The Management Of Patients With Schizophrenia Or Schizoaffective Disorder In General Psychiatric Practices III Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-087 LT A Prospective, Multicenter, Open-Label Study Of Aripiprazole In The Management Of Patients With Schizophrenia Or Schizoaffective Disorder In General Psychiatric Practices III Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-089 A Randomized, Multicenter, Double-Blind, Placebo Controlled Study Of The Efficacy And Safety Of Aripiprazole In The Maintenance Of Abstinence From Alcohol In Subjects With Alcoholism III Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-091 ST Open Labell Acceptability Study Of Aripiprazole Oral Solution In Patients With Chronic Schizophrenia III Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-096 LT A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Aripiprazole In The Treatment Of Patients With Bipolar I Disorder With A Major Depressive Episode III Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-096 ST A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Aripiprazole In The Treatment Of Patients With Bipolar I Disorder With A Major Depressive Episode III Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-100 A Prospective, Multicenter, Open-Label Study Of Aripiprazole In The Management Of Patients With Schizophrenia In General Psychiatric Practices. Broad Effectiveness Trial With Aripiprazole - Beta III Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-113 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Three Fixed Doses Of Aripiprazole In The Treatment Of Patients With Acute Schizophrenia IV Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-114 ST A Randomized Open Label Acceptability Study Of Aripiprazole Oral Disintegrating Tablets In The Treatment Of Stable Patients With Schizophrenia III Result
Psychotic Disorders ABILIFY® (aripiprazole)
 CN138-122 A Multicenter, Randomized, Double-Blind Study On The Effects Of Aripiprazole On Overweight Pateints Treated With Olanzapine For Schizophrenia Or Schizoaffective Disorder III Publica-
tion
Reference
/Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-125 A Prospective Multicenter, Open-Label Study Of Aripiprazole In The Management Of Patients With Schizophrenia In General Psychiatric Practices IV Result
Dementia ABILIFY® (aripiprazole)
 CN138-131 A Double-Blind Placebo Controlled Pilot Tolerability Study Of Intramuscular Aripiprazole In The Treatment Of Acutely Agitated Patient's With A Diagnosis Of Alzheimer's, Vascular Or Mixed Dementia II Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-134 LT Efficacy Of Aripiprazole In Combination With Valproate Or Lithium In The Treatment Of Mania In Patients With Bipolar I Disorder Partially Nonresponsive To Valproate Or Lithium Monotherapy III Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-134 ST Efficacy Of Aripiprazole In Combination With Valproate Or Lithium In The Treatment Of Mania In Patients With Bipolar I Disorder Partially Nonresponsive To Valproate Or Lithium Monotherapy III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-135 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Aripiprazole Monotherapy In The Treatment Of Acutely Manic Patients With Bipolar I Disorder III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-135 LT A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Aripiprazole Monotherapy In The Treatment Of Acutely Manic Patients With Bipolar I Disorder III Result
Depression ABILIFY® (aripiprazole)
 CN138-139 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of Aripiprazole As Adjunctive Therapy In The Treatment Of Patients With Major Depressive Disorder. III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-146 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Aripiprazole In The Treatment Of Patients With Bipolar I Disorder With A Major Depressive Episode. III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-146 LT A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Aripiprazole In The Treatment Of Patients With Bipolar I Disorder With A Major Depressive Episode. Cn138-146 Lt Is The 26-Week Open Label Extension Phase Of The Above Titled Protocol, Cn138-146 St. There Is No Combo Tx. That Term Is A Carryover From An Initial Design Strategy That Was Not Adopted. III Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-152 A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole And Standard Of Care In The Management Of Community-Treated Schizophrenic Patients (Schizophrenia Trial Of Aripiprazole: The Star Study) III Publica-
tion
Reference
/Result
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-162 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Of Aripiprazole Monotherapy In The Treatment Of Acutely Manic Patients With Bipolar I Disorder III Publica-
tion
Reference
/Result
Depression ABILIFY® (aripiprazole)
 CN138-163 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of Aripiprazole As Adjunctive Therapy In The Treatment Of Patients With Major Depressive Disorder III Publica-
tion
Reference
/Result
Depression ABILIFY® (aripiprazole)
 CN138-164 ST A Multicenter, Long-Term, Open-Label Study To Assess The Safety And Tolerability Of Aripiprazole As Adjunctive Therapy In The Treatment Of Outpatients With Major Depressive Disorder III Result
Depression ABILIFY® (aripiprazole)
 CN138-165 ST A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of Aripiprazole As Adjunctive Therapy In The Treatment Of Patients With Major Depressive Disorder III Publica-
tion
Reference
/Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-166 A Prospective, Multicenter,Ol Study To Evaluate The Effectiveness And The Effect On Cognitive Functioning Of A Ttmt With Aripiprazole When The Product Is Administered To In A Broad Range Of Schizophrenic Patients. IV Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-169 ST A Comparative, Randomized, Open-Label, Multicenter Study On The Efficacy And Safety Of Switch Treatment With Aripiprazole In Schizophrenic Out-Patients Who Are Experiencing Insufficient Efficacy With Risperidone And/Or Safety And Tolerability Issues While On Risperidone. IV Publica-
tion
Reference
/Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-170 LT A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study On The Effect On Weight Of Adjunctive Treatment With Aripiprazole In Patients With Schizophrenia IV Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-170 ST A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study On The Effect On Weight Of Adjunctive Treatment With Aripiprazole In Patients With Schizophrenia IV Result
Mixed Anxiety Depression ABILIFY® (aripiprazole)
 CN138-177 Effects Of Aripiprazole On The Steady-State Pharmacokinetics Of Escitalopram Or Venlaxfaxine In Depressive Or Anxiety-Disorder Subjects I Result
Autism ABILIFY® (aripiprazole)
 CN138-178 ST A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study Of Aripiprazole Flexibly Dosed In The Treatment Of Children And Adolescents With Autistic Disorder III Publica-
tion
Reference
/Result
Autism ABILIFY® (aripiprazole)
 CN138-179 ST A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses Of Aripiprazole In The Treatment Of Children And Adolescents With Autistic Disorder III Publica-
tion
Reference
/Result
Autism ABILIFY® (aripiprazole)
 CN138-180 ST A 52-Week, Open-Label, Multicenter Study Of The Safety And Tolerability Of Aripiprazole Flexibly Dosed In The Treatment Of Children And Adolescents With Autistic Disorder III No Data Available
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-189 ST Efficacy Of Aripiprazole In Combination With Lithium Or Valproate In The Long-Term Treatment Of Mania In Patients With Bipolar I Disorder Partially Nonresponsive To Lithium Or Valproate Monotherapy IV No Data Available
Bipolar Disorder ABILIFY® (aripiprazole)
 CN138-392 ST A Multicenter, Double-Blind, Study On The Efficacy And Safety Of Aripiprazole In Combination With Lamotrigine In The Long-Term Maintenance Treatment Of Patients With Bipolar I Disorder With A Recent Manic Or Mixed Episode IV No Data Available
Schizophrenia ABILIFY® (aripiprazole)
 CN138-397 ST A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Of Aripiprazole Used As Dual Therapy In The Treatment Of Patients With Chronic Stable Schizophrenia Or Schizoaffective Disorder Demonstrating An Inadequate Response To Quetiapine Or Risperidone Monotherapy IV Publica-
tion
Reference
/Result
Schizophrenia ABILIFY® (aripiprazole)
 CN138-489 ST A 16-Week, Multicenter, Randomized, Open-Label Study To Assess The Effects Of Aripiprazole Versus Other Atypical Antipsychotics In The Treatment Of Schizophrenic Patients With Metabolic Syndrome IV Result
Schizophrenia, Acute Exacerbation ABILIFY® (aripiprazole)
 CN138-564 ST A 16-Week, Randomized, Controlled Trial Of The Effect Of Aripiprazole Versus Standard Of Care On Non-Hdl Cholesterol Among Patients With Schizophrenia And Bipolar I Disorder Who Have Pre-Existing Metabolic Syndrome III No Data Available
Parkinson's Disease Sinemet® CR
CN158-001 ST An Open Label, Multiple-Dose Study To Determine The Plasma Levodopa Profiles Of Sinemet Cr At 4 Daily Dose Levels In Healthy Subjects I Result
Bipolar Disorder ABILIFY® (aripiprazole)
 Cn138-077 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Aripiprazole In The Treatment Of Acutely Manic Patients With Bipolar Disorder III Result
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-E106-96B A Double-Blind, Placebo-Controlled, Parallel Assessment Of The Safety And Efficacy Of The Selegiline Transdermal System In Patients With Major Depression III Publica-
tion
Reference
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-E113-98B A Double-Blind, Placebo-Controlled, Parallel Assessment Of The Safety And Efficacy Of The Selegiline Transdermal System In Subjects With Major Depression III Result
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-E114 A Double-Blind, Placebo-Controlled, Parallel-Group Assessment Of The Safety And Efficacy Of Two Doses Of The Selegiline Transdermal System (10 Mg And 20 Mg) In Patients With Major Depression III Result
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-P0052 A Phase III Flexible Dose Titration Study Of The Safety And Efficacy Of The Selegiline Transdermal System In Patients With Major Depression. III Result
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-P0204 A Phase III, Open-Label Study Of The Safety, Tolerability, And Efficacy Of The Selegiline Transdermal System (20mg/20cm2, 30mg/30cm2, Or 40mg/40cm2) In Subjects With Major Depression. III Result
Depression, Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-P9804 A Double-Blind, Placebo-Controlled, Parallel Assessment Of The Safety And Efficacy Of The Selegiline Transdermal System In Patients With Major Depression III Publica-
tion
Reference
Depression, Recurrent Major Depressive Disorder EMSAM® (selegiline transdermal system)
 S9303-P9806 A Double-Blind, Placebo-Controlled, Parallel-Group Assessment Of The Selegiline Transdermal System In The Reappearance Of Symptoms Associated With Major Depression III Publica-
tion
Reference